Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85664 | 0.98 | MAPT (0.60) | MAPTMEN1KMT2ARAB9AAKR1C3 | |
| SCHEMBL29929946 | 0.95 | MEN1 (0.56) | MAPTMEN1KMT2ARAB9AAKR1C3 | |
| SCHEMBL77999 | 0.95 | MEN1 (0.56) | MAPTMEN1KMT2ARAB9AAKR1C3 | |
| SCHEMBL11183530 | 0.88 | MAPT (0.53) | MAPTMEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL17206015 | 0.85 | MAPT (0.43) | MAPTMEN1KMT2ARAB9AAKR1C3 | |
| SCHEMBL8317379 | 0.82 | MAPT (0.56) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL85661 | 0.81 | KMT2A (0.57) | MAPTMEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL7549606 | 0.81 | MAPT (0.58) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL30962697 | 0.80 | SIRT6 (0.62) | MAPTMEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL85229 | 0.78 | MAPT (0.49) | MAPTMEN1KMT2ARAB9AAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615756-A | 1- (4-nitrophenyl) piperidine-2-ketone and synthetic method and application thereof | 南京红杉生物科技有限公司 | 2019-12-27 | — | — | CN | claimed |
| WO-2015162551-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | MYLAN LABORATORIES LTD (IN) | 2015-10-29 | — | — | WO | claimed |
| CN-103159670-A | Synthetic method of apixaban intermediate 1-(4-nitrobenzophenone)-2-piperidone | LANZHOU CHEM PHYS INST | 2013-06-19 | — | — | CN | claimed |
| CN-120483910-A | Apixaban intermediate 5, 6-dihydro-3- (4-morpholinyl) -1- (4-nitrophenyl) -2 (1H) -piperidone and synthetic method thereof | 成都化润药业有限公司 | 2025-08-15 | — | — | CN | disclosed |
| CN-116375703-B | Synthesis process of apixaban | 常州制药厂有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-115215816-B | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116253675-B | Synthesis method of N-substituted-2-piperidone | 山东信谊制药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116375703-A | Synthesis process of apixaban | 常州制药厂有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116253675-A | Synthesis method of N-substituted-2-piperidone | 山东信谊制药有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-115215816-A | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022218348-A1 | METHOD FOR SYNTHESIZING LACTAM COMPOUNDS | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2022-10-20 | — | — | WO | disclosed |
| US-20040097550-A1 | Biurethane derivatives | MERCK PATENT GMBH (DE) | 2004-05-20 | — | — | US | disclosed |
| US-20040087582-A1 | Phenyl derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2004-05-06 | — | — | US | disclosed |
| EP-1385818-A2 | BIURETHANE DERIVATIVES | MERCK PATENT GmbH (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1351938-A1 | PHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-10-15 | — | — | EP | disclosed |
| US-6509358-B2 | For therapy of metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma | WYETH | 2003-01-21 | — | — | US | disclosed |
| WO-2002074735-A2 | BIURETHANE DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002057236-A1 | PHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-07-25 | — | — | WO | disclosed |
| US-20020022641-A1 | Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | disclosed |
| WO-2002006230-A2 | PIPERIDINO-PHENYL AMINO SQUARATE AND THIADIAZOLE DIOXIDE BETA-3 ADRENERGIC RECEPTOR AGONISTS | AMERICAN HOME PROD (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097550-A1 | Biurethane derivatives | F2, F11, BRCA1 | MAPT 3798/4885MEN1 871/4885KMT2A 3737/4885 |
| US-20040087582-A1 | Phenyl derivatives | F2, F11, SERPINC1 | MAPT 4360/4885MEN1 2997/4885KMT2A 2252/4885 |
| US-20020022641-A1 | Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists | ADRB1, ADRB3, GPR119 | MAPT 1596/4885MEN1 3600/4885KMT2A 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.